This HTML5 document contains 57 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n15http://localhost/temp/predkladatel/
n12http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n13http://linked.opendata.cz/ontology/domain/vavai/
n16http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n11http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11150%2F08%3A00107075%21RIV09-MZ0-11150___/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n9http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11150%2F08%3A00107075%21RIV09-MZ0-11150___
rdf:type
n13:Vysledek skos:Concept
dcterms:description
Described the effect reduced dose interferon-alpha 2a with bevacizumab in patients with metastatic cell carcinoma. Described the effect reduced dose interferon-alpha 2a with bevacizumab in patients with metastatic cell carcinoma. Popsán efekt redukce dávky interferonu na účinnost v kombinaci s bevacizumabem u karcinomu ledvin.
dcterms:title
First-line bevacizumab combined with reduced dose interferon-alpha 2a is active in patients with metastatic renal cell carcinoma First-line bevacizumab combined with reduced dose interferon-alpha 2a is active in patients with metastatic renal cell carcinoma Kombinace bevacizumabu s dávkami interferonu-alfa 2a u pacientů s karcinomem ledvin
skos:prefLabel
Kombinace bevacizumabu s dávkami interferonu-alfa 2a u pacientů s karcinomem ledvin First-line bevacizumab combined with reduced dose interferon-alpha 2a is active in patients with metastatic renal cell carcinoma First-line bevacizumab combined with reduced dose interferon-alpha 2a is active in patients with metastatic renal cell carcinoma
skos:notation
RIV/00216208:11150/08:00107075!RIV09-MZ0-11150___
n4:aktivita
n17:Z
n4:aktivity
Z(MZ0FNHK2005)
n4:cisloPeriodika
8
n4:dodaniDat
n9:2009
n4:domaciTvurceVysledku
n12:5290791
n4:druhVysledku
n18:J
n4:duvernostUdaju
n14:S
n4:entitaPredkladatele
n11:predkladatel
n4:idSjednocenehoVysledku
368119
n4:idVysledku
RIV/00216208:11150/08:00107075
n4:jazykVysledku
n8:eng
n4:klicovaSlova
abtiangiogenic therapy; bevacizumab; interferon-alpha; renal cell carcinoma; vascular endothelial growth factor (VEGF)
n4:klicoveSlovo
n5:bevacizumab n5:abtiangiogenic%20therapy n5:renal%20cell%20carcinoma n5:vascular%20endothelial%20growth%20factor%20%28VEGF%29 n5:interferon-alpha
n4:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n4:kontrolniKodProRIV
[7603BDC81442]
n4:nazevZdroje
Annals of Oncology
n4:obor
n7:FD
n4:pocetDomacichTvurcuVysledku
1
n4:pocetTvurcuVysledku
15
n4:rokUplatneniVysledku
n9:2008
n4:svazekPeriodika
19
n4:tvurceVysledku
Delva, R. McKendrick, J. Filipek, M. Sevin, E. Bracarda, S. Melichar, Bohuslav Ravaud, A. Santoro, A. Koralewski, P. Pisa, P. Escudier, B. Pluzanska, A. Negrier, S. Chevreau, C. Szczylik, C.
n4:wos
000258136800017
n4:zamer
n16:MZ0FNHK2005
s:issn
0923-7534
s:numberOfPages
7
n15:organizacniJednotka
11150